Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program
Inmagene emerges from stealth with a clinical psoriasis program from Swedish biotech Affibody
Inmagene emerged from stealth with a clinical psoriasis program from Swedish biotech Affibody.
Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program it in-licensed from Swedish biotech Affibody. The candidate, IMG-020, is expected to be cheaper to manufacture and more convenient to administer than marketed antibodies against the same target.
According to Inmagene, biologics account for only 17% of pharmaceutical sales for autoimmune diseases in China compared with 80%